Rapid Symptom Relief.1
Durable Clinical Remission.1
Significant Endoscopic Control.1

Put Crohn's in check and keep it there.

Results were measured at Weeks 12 and 52.1

INDICATION

RINVOQ is indicated for the treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.

Limitations of Use: RINVOQ is not recommended for use in combination with other Janus kinase (JAK) inhibitors, biological therapies for Crohn’s disease, or with potent immunosuppressants such as azathioprine and cyclosporine.

Significant Endoscopic Control1

Visible mucosal improvement with endoscopic response* and endoscopic remission† endpoints achieved at Weeks 12 and 52.

Check Out Endoscopic Outcomes

Durable Clinical Remission1

Clinical remission‡ achieved at Weeks 12 and 52.

Check Out Clinical Remission Results

Rapid Symptom Relief1

Clinical response§ achieved at Week 2.

Check Out Symptom Relief Results

Well-Studied Safety1,2

Studied since 2012 with 26 clinical trials across 8 approved indications in rheumatology, dermatology, and gastroenterology.

Check Out Safety Data

*Endoscopic response was defined as a decrease in SES-CD >50% from baseline, or a decrease of at least 2 points for subjects with a baseline score of 4 and isolated ileal disease, based on central reading. The sections evaluated on endoscopy are the: rectum, sigmoid and left colon, transverse colon, right colon and ileum (per SES-CD assessment).

†Endoscopic remission was defined as SES-CD ≤4 and no subscore >1 in any individual variable, as scored by a central reviewer.

‡Clinical remission was defined as CDAI <150 points.

§Clinical response was defined as a reduction of CDAI ≥100 points from baseline.

CDAI=Crohn's Disease Activity Index; IR=intolerance or inadequate response; SES-CD=Simple Endoscopic Score for Crohn's Disease; TNFi=tumor necrosis factor inhibitor.